TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hutterite Influenza Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Group A:~Inclusion Criteria:~* Hutterites other than the healthy children who will be immunized. Although this category as a whole will be used to assess indirect benefit of the vaccine in the main analysis, Hutterites at high risk for influenza complications within this category will be assessed in a separate analysis. These are defined as anyone in one or more of the following groups:~* individuals aged ≥ 65 years~* children 23 months of age or less~* anyone with ≥ 1 of the following conditions severe enough to require regular medical follow-up or hospital care:~  * chronic cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis, and asthma)~ * diabetes mellitus and other metabolic diseases~ * cancer~ * immunodeficiency~ * immunosuppression (due to underlying disease and/or therapy)~ * renal disease~ * anemia~ * hemoglobinopathy~ * any condition that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration.~Exclusion Criteria:~* There are no exclusion criteria for this category of participants.~Group B:~Inclusion Criteria:~* Healthy children aged 36 months to 15 years who will be immunized as part of the intervention.~Exclusion Criteria:~* Anaphylactic reaction to a previous dose of influenza vaccine~* Anaphylactic reaction to hepatitis A vaccine~* Anaphylactic reaction to neomycin~* Known IgE-mediated hypersensitivity to eggs manifested as hives~* Swelling of the mouth and throat, difficulty in breathing, hypotension, or shock~* Guillain-Barré syndrome within eight weeks of a previous influenza vaccine.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Influenza (Type: EXPERIMENTAL): Inactivated Influenza vaccination
- Control (Type: PLACEBO_COMPARATOR): Hepatitis A vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Induction Versus Expectant Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Nulliparous - no previous pregnancy beyond 20 weeks~2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age.~3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days inclusive based on clinical information and evaluation of the earliest ultrasound.~Exclusion Criteria:~1. Project gestational age at date of first ultrasound is \> 20 weeks 6 days~2. Plan for induction of labor prior to 40 weeks 5 days~3. Plan for cesarean delivery or contraindication to labor~4. Breech presentation~5. Signs of labor (regular painful contractions with cervical change)~6. Fetal demise or known major fetal anomaly~7. Heparin or low-molecular weight heparin during the current pregnancy~8. Placenta previa, accreta, vasa previa~9. Active vaginal bleeding greater than bloody show~10. Ruptured membranes~11. Cerclage in current pregnancy~12. Known oligohydramnios, defined as AFI \< 5 or MVP \< 2~13. Fetal growth restriction, defined as EFW \< 10th percentile~14. Known HIV positivity because of modified delivery plan~15. Major maternal medical illness associated with increased risk for adverse pregnancy outcome (for example, any diabetes mellitus, lupus, any hypertensive disorder, cardiac disease, renal insufficiency)~16. Refusal of blood products~17. Participation in another interventional study that influences management of labor at delivery or perinatal morbidity or mortality~18. Delivery planned elsewhere at a non-Network site

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Expectant Management (Type: NO_INTERVENTION): Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
- Elective Induction of Labor (Type: OTHER): Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older infected with HIV and weigh at least 40 kg.~* Plasma HIV RNA viral load of 1000 copies/mL or greater and CD4 count of 100 cells/mL or greater.~* Be willing to use two forms of contraception throughout study.~* No previous exposure to antiretroviral (ARV) drugs~Exclusion Criteria:~* Pregnancy or breastfeeding~* Physical or psychiatric disability~* Proven or suspected acute hepatitis within 30 days prior to study entry~* Active AIDS-defining opportunistic infection or disease~* History of acute or chronic pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA based on 2010 ACR/EULAR for RA for at least a 4 month duration.~* Moderately to severely active RA based on local standard of care.~Exclusion Criteria:~-Evidence of untreated or inadequately treated latent or active TB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm 1 (Type: EXPERIMENTAL): Subcutaneous (SC) injection given every other week
- Treatment Arm 2 (Type: ACTIVE_COMPARATOR): SC injection given every other week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indomethacin Versus Nifedipine for Preterm Labor Tocolysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton and twin gestations~* Intact amniotic membranes~* No contra-indications to tocolysis~* 24-34 weeks gestation by last menstrual period and/or ultrasound~* Documented cervical change, and regular painful uterine contractions at least every 5 minutes, or at least 2 cm cervical dilation and 80% effacement~Exclusion Criteria:~* Ruptured amniotic membranes~* Signs/symptoms of chorioamnionitis (maternal temperature greater than 100.4 F/38.0 C, fetal tachycardia, uterine tenderness)~* Non-reassuring fetal heart rate tracings~* Contra-indications to indomethacin or nifedipine~* Contra-indications to tocolysis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: ACTIVE_COMPARATOR): 50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
- Nifedipine (Type: ACTIVE_COMPARATOR): 30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 14 days after first course of antenatal steroids;~* Less than 34 weeks of gestation;~* Identified by primary physician as continued risk for preterm delivery;~* Informed consent~Exclusion Criteria:~* Major congenital anomalies~* Multiple gestation of triplets or greater~* Mother with insulin dependent diabetes

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses
- B (Type: PLACEBO_COMPARATOR): Placebo dose intramuscular q 24 hours x 2 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed.~* Male and female ≥ 40 years~* Current or ex-smokers who have a smoking history of at least 10 pack years (Ten pack years are defined as 20 cigarettes per day for 10 years or 10 cigarettes per day for 20 years). An ex-smoker is defined as a patient who has not smoked for ≥ 6 months at visit 1~* Confirmed diagnosis of COPD and post-bronchodilator FEV1 ≥ 30% and \< 80% of the predicted normal value and post-bronchodilator FEV1/FVC \< 0.70 at visit 1~* Treated with salmeterol/fluticasone 50/500 µg b.i.d. for at least 3 months prior to visit 1~* Documented CAT score of ≥ 10 at Visit 1 and 2~Exclusion Criteria:~* Treatment with any LAMA in the 2 weeks prior to visit 1~* Presence of any contraindication, warning, precaution, hypersensitivity in the approved prescribing information for salmeterol/fluticasone~* Prior or current diagnosis of asthma~* More than one COPD exacerbation requiring treatment with antibiotics and/or systemic corticosteroids and/or hospitalization in the year prior to Visit 1~* Patients who developed a COPD exacerbation of any severity within the 6 weeks before the screening (Visit 1) or between screening (Visit 1) and start of treatment (Visit 2) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation~* Respiratory tract infection within 4 weeks prior to Visit 1~* Respiratory tract infection between Visit 1 and 2. Patients can be re-screened 4 weeks after resolution of the infection~* Requiring oxygen therapy prescribed for \>12 hours per day~* Onset of respiratory symptoms, including a COPD diagnosis prior to age 40 years

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 110/50 micrograms (Type: EXPERIMENTAL): QVA149 110/50 micrograms o.d. Capsules for inhalation
- salmeterol/fluticasone 50/500 micrograms (Type: ACTIVE_COMPARATOR): salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Caffeine on the Narcoleptic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Case -group should be Narcoleptic with cataplexy~Exclusion Criteria:~* Individuals older than 45 years or younger than 18 years old.~* Individuals complaining of any diseases or conditions that affect their dietary intake, as such : renal failure, liver failure, malabsorption problems, cardiac diseases ... etc.~* Individuals having hypersensitivity to caffeine.~* Individuals with medical conditions that cause sleepiness (like hypothyroidism) and pregnant or lactating females will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: EXPERIMENTAL): Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants.
- Fiber (Type: PLACEBO_COMPARATOR): Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Not currently on durg therapy for type 2 diabetes~* Body mass index (BMI) in the range 22-45~* Blood glucose criteria must be met~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular conditions~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- Metformin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal female, between 18 and 49 years of age, inclusive, at the time of signing consent.~2. Clinical diagnosis of endometriosis (laparoscopy or laparotomy) performed within 10 years of entry into Washout (if applicable) or Screening.~3. Agrees to use required birth control methods during the entire length of participation in the study.~4. Subject has a Composite Pelvic Signs and Symptoms Score total score of ≥ 6 at Screening with a score of at least 2 for dysmenorrhea AND at least 2 for non-menstrual pelvic pain. 5. Subjects must have at least two menstrual cycles 24 to 38 days within the Screening Period, prior to Day 1~Exclusion Criteria:~1. Subject is pregnant or breast feeding or is planning a pregnancy within the next 24 months or is less than 6 months postpartum, post-abortion, or post-pregnancy at the time of entry into the Screening Period.~2. Subject has a history of previous non-response to Gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, Depot Medroxyprogesterone Acetate, or aromatase inhibitors as assessed by subject report of no improvement in dysmenorrhea or non-menstrual pelvic pain (subject report of partial response to or side effects from these agents is not exclusionary).~3. Subject has chronic pelvic pain that is not caused by endometriosis that requires chronic analgesic or other chronic therapy, or that would interfere with the assessment of endometriosis related pain.~4. Clinically significant gynecologic condition identified on Screening transvaginal ultrasound or endometrial biopsy.~5. Subject has a history of osteoporosis or other metabolic bone disease.~6. Subject has a current history of undiagnosed abnormal genital bleeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg QD (Type: EXPERIMENTAL): Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
- Elagolix 200 mg BID (Type: EXPERIMENTAL): Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID for the 6-month Treatment Period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Supplementation to Reduce Preschoolers Anemia: Comparison Between Intermittent and Cyclic Procedure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participants of the study were children with ages ranging from 24 to 59 months old that attended four local public day care centers~Exclusion Criteria:~* Presence of infection or reported infections within two weeks prior to the intervention~* Anemia lower than 7.0 g/dL and children taking medications containing ferrous sulfate

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- Group 1:iron weekly supplementation (Type: ACTIVE_COMPARATOR): None
- Group 2: cycle supplementation (Type: ACTIVE_COMPARATOR): two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing COVID-19 Mental Health Problems Among US Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* English speakers, veterans (military experience) aged 18-80, US residents~Exclusion Criteria:~* non-English speakers, age less than 18 or more than 80

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Video-based intervention (Type: EXPERIMENTAL): A brief video about coping with COVID-19 stress presented to the participants
- vignette intervention (Type: EXPERIMENTAL): A brief vignette about coping with COVID-19 stress presented to the participants
- Control (Type: NO_INTERVENTION): Only assessment, no intervention arrm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A history of stable documented CAD~* Currently non-smoking males and females ages 30 to 85 years inclusive.~  o Female subjects of child-bearing potential (neither pregnant nor breast-feeding) must be using adequate birth control during study conduct.~* Chronic concomitant medications must be stable for at least 2 months prior to screening~* HDL-C \< 50 mg/dL for men and \< 55 mg/dL for women~* Body Mass Index (BMI) of approximately 18 to 35 kg/m\^2; and a total body weight \>= 50 kg (110 lbs) and \<= 110 kg (approximately 242 lbs)~Exclusion Criteria:~* Myocardial infarction, stroke, or coronary intervention/revascularization procedure within 6 months prior to dosing.~* Chronic heart failure (\> New York Heart Association (NYHA) Functional Classification II).~* Ventricular tachyarrhythmias.~* Uncontrolled Type 2 (HbA1c \> 8.5%) or Type 1 diabetes mellitus.~* History of febrile illness within 5 days prior to dosing.~* History of regular alcohol consumption exceeding 10 drinks per week.~* 12-lead ECG demonstrating QTc \> 500 msec at screening.~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ACP-501 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete